Nataline Sarkisyan died yesterday. She was seventeen years old. She died because her health insurance provider, CIGNA, backed away from a previously authorized liver transplant that could have saved her life.
Nataline was a cancer patient, diagnosed with Leukemia, and had received a bone marrow transplant from her brother which lead to complications that shut down her liver. CIGNA secured a matching liver donor and doctors were ready to preform the operation when Nataline aquired a lung infection. Though her doctors felt comfortable going forward with the transplant, CIGNA dubbed it "too experimental" and backed off.
Nataline's story throws the horrors of the American profit-driven healthcare system into share relief. Not only did CIGNA back away from a viable procedure that could have saved the life of a child, they did so against the advice of the doctors overseeing that child's care.
CIGNA healthcare killed Nataline Sarkisyan.
Though the Sarkisyan family has released few of Nataline's medical records to the press, what details there are suggest that, with a transplant and proper care, Nataline might have made a full recovery. The Leukemia, liver failure, and lung infection paint a deceptively dismal picture; in all likelihood, Nataline had a fighting chance until her transplant was denied.
Nataline had already received a bone marrow transplant which means that her immune system was weakened but her cancer was very likely beaten - in remission as the doctors put it - or close to it. Liver complications are common-place after a bone marrow transplant and Nataline's doctors and insurance provider were well aware of that possibility. Her weakened immune system put her at risk for an opportunistic infection (like the lung infection that changed CIGNA's mind) which is also a common transplant complication.
In short, there is no indication that anything about Nataline's condition going into the planned transplant was "experimental." "Textbook," might be a more appropriate turn of phrase.
While perhaps the most recent and certainly among the most sympathetic, Nataline is not the only victim of America's for-profit health-care industry. The problem is not one of private versus public or single versus multi-payer, but simply one of mission and goal.
Ultimately, CIGNA is responsible to its stockholders, not its customers.
Just ask the thousands of other patients and families who, after years of premiums, find themselves somehow cheated out of the coverage they'd counted on and paid for all those years. Just ask the accountants who processed the SEC filings on CIGNA's $16,547,000,000 in revenue for 2006 . Just ask the board of directors.
As the leadership of a publicly held, for-profit company and it is the responsibility of the CIGNA board of directors to ensure that the company's various investors receive a reasonable rate of return.
Nataline Sarkisyan paid for that return.



